2025 · 3rd Quarter (July 1 - Sep 30)

T1INTERNATIONAL USA

Filed by T1INTERNATIONAL USA.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 15, 2025
Income: Not reported
Expenses: Not reported
Registrant: T1INTERNATIONAL USA
Client: T1INTERNATIONAL USA
Filing UUID: 59b6b9db-e3dd-4040-91ad-b9d375e7a383
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)

Literal federal measure citations: HR 1, S.1040, S.1041, S.1095, S.1096, H.R.3160, S.1553, H.R.3152, S.1546, S.1818, S.1753, S.1218

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.